Used in the treatment of moderate to severe plaque psoriasis by specifically targeting and neutralizing the interleukin-23 (IL-23) cytokine. By inhibiting IL-23, it helps reduce the inflammatory response responsible for the rapid skin cell growth and inflammation characteristic of psoriasis. This antibody is administered via subcutaneous injection and is designed for long-term management, offering sustained skin clearance in many patients. It is also being investigated for use in other autoimmune conditions involving the IL-23 pathway, such as psoriatic arthritis and inflammatory bowel disease.